Swiss National Bank Buys 1,318,900 Shares of Merck & Co., Inc. (NYSE:MRK)
Swiss National Bank Buys 1,318,900 Shares of Merck & Co., Inc. (NYSE:MRK)
Swiss National Bank raised its stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 13.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 10,940,532 shares of the company's stock after acquiring an additional 1,318,900 shares during the period. Swiss National Bank owned approximately 0.43% of Merck & Co., Inc. worth $897,671,000 as of its most recent SEC filing.
據瑞士央行最近提交給美國證券交易委員會的文件顯示，該行今年第一季度將默克公司(Merck&Co.，Inc.)股票持股比例提高了13.7%。該公司在此期間增持了1,318,900股後，持有該公司10,940,532股股票。截至最近提交的美國證券交易委員會申請文件，瑞士國家銀行持有默克公司約0.43%的股份，價值897,671,000美元。
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Bromfield Sneider Wealth Advisors purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at about $79,000. Hikari Power Ltd increased its position in shares of Merck & Co., Inc. by 5.0% during the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company's stock valued at $1,939,000 after purchasing an additional 1,130 shares during the last quarter. ACG Wealth increased its position in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. ACG Wealth now owns 13,523 shares of the company's stock valued at $1,110,000 after purchasing an additional 722 shares during the last quarter. Mascoma Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 36.4% during the 1st quarter. Mascoma Wealth Management LLC now owns 926 shares of the company's stock valued at $76,000 after purchasing an additional 247 shares during the last quarter. Finally, WealthBridge Investment Counsel Inc. increased its position in shares of Merck & Co., Inc. by 4.1% during the 1st quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company's stock valued at $7,206,000 after purchasing an additional 3,475 shares during the last quarter. Institutional investors own 72.88% of the company's stock.
其他幾家對衝基金和其他機構投資者也買賣了該股的股票。Bromfield Sneider Wealth Advisors在第一季度購買了默克公司(Merck&Co.，Inc.)新股，價值約7.9萬美元。Hikari Power Ltd在第一季度增持了默克公司股票5.0%的頭寸。Hikari Power Ltd現在擁有該公司23,630股股票，價值1,939,000美元，此前該公司在上個季度又購買了1,130股股票。ACG Wealth在第一季度增持了默克公司股票5.6%。ACG Wealth在上個季度又購買了722股，現在擁有13,523股該公司股票，價值111萬美元。Mascoma Wealth Management LLC在第一季度將其在默克公司股票的持倉增加了36.4%。Mascoma Wealth Management LLC在上個季度額外購買了247股後，現在擁有926股該公司股票，價值7.6萬美元。最後，WealthBridge Investment Counsel Inc.在第一季度將其持有的默克公司股票頭寸增加了4.1%。WealthBridge Investment Counsel Inc.現在持有87,820股該公司股票，價值7,206,000美元，該公司在上個季度又購買了3,475股。機構投資者持有該公司72.88%的股票。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several equities research analysts have recently commented on the stock. Mizuho assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They set a "buy" rating and a $100.00 price target for the company. Cowen increased their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a "market perform" rating in a report on Monday, June 27th. UBS Group increased their target price on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a "neutral" rating in a report on Monday, July 18th. SVB Leerink reissued an "outperform" rating and issued a $102.00 target price on shares of Merck & Co., Inc. in a report on Monday, June 6th. Finally, Daiwa Capital Markets raised shares of Merck & Co., Inc. from a "neutral" rating to a "buy" rating and increased their target price for the stock from $89.00 to $102.00 in a report on Wednesday, July 6th. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $97.44.
幾位股票研究分析師最近對該股發表了評論。瑞穗在6月24日星期五的一份研究報告中對默克公司的股票進行了報道。他們為該公司設定了“買入”評級和100.00美元的目標價。考恩將默克公司股票的目標價從95美元上調至102.00美元，並在6月27日星期一的一份報告中給出了該股的“市場表現”評級。瑞銀集團在7月18日週一的一份報告中將默克公司股票的目標價從76.00美元上調至98.00美元，並給予該股“中性”評級。SVB Leerink在6月6日週一的一份報告中重新發布了對默克公司的評級，並將默克公司的股票目標價定為102.00美元。最後，在7月6日週三的一份報告中，大和資本市場將默克公司的股票評級從中性上調至買入，並將該股的目標價從89美元上調至102.00美元。8名股票研究分析師對該股的評級為持有，9名分析師給予該公司買入評級，2名分析師給予該公司強烈的買入評級。根據MarketBeat的數據，該股目前的平均評級為“適度買入”，共識目標價為97.44美元。
Merck & Co., Inc. Stock Up 0.7 %
默克公司股價上漲0.7%
Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts' consensus estimates of $1.69 by $0.18. The firm had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 50.02% and a net margin of 29.00%. The company's quarterly revenue was up 28.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.31 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 7.31 EPS for the current fiscal year.
默克公司(紐約證券交易所代碼：MRK-GET評級)最近一次公佈收益報告是在7月28日星期四。該公司公佈本季度每股收益為1.87美元，比分析師普遍預期的1.69美元高出0.18美元。該公司本季度營收為145.9億美元，而市場普遍預期為138.5億美元。默克公司的股本回報率為50.02%，淨利潤率為29.00%。與去年同期相比，該公司的季度收入增長了28.0%。去年同期，該公司每股收益為1.31美元。股票分析師預計，作為一個整體，默克公司本財年每股收益將達到7.31歐元。
Merck & Co., Inc. Dividend Announcement
默克公司宣佈分紅
The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.69 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.16%. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.
該公司最近還宣佈了季度股息，將於10月7日(星期五)支付。9月15日(星期四)登記在冊的股東將獲得每股0.69美元的股息。除息日為9月14日星期三。這意味着年化股息為2.76美元，股息收益率為3.16%。默克公司目前的股息支付率為42.27%。
Merck & Co., Inc. Profile
默克公司簡介
(Get Rating)
(獲取評級)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的醫療保健公司。它通過兩個部門運作，製藥和動物健康。製藥部門提供腫瘤學、醫院急性護理、免疫學、神經科學、病毒學、心血管和糖尿病等領域的人類健康藥物產品，以及疫苗產品，如預防性兒科、青少年和成人疫苗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於默克公司的研究報告(MRK)
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看還有哪些對衝基金持有MRK嗎？訪問HoldingsChannel.com獲取默克公司(NYSE：MRK-GET Rating)的最新13F文件和內幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對默克公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。